Health-care companies shares ticked down as traders rotated out of sectors more sensitive to shifts in Federal Reserve rate policy.

Novartis said it received priority review for Fabhalta as a potential treatment for IgA nephropathy, a rare kidney disease.

Shares of Ultragenyx Pharmaceutical slid after troublesome side effects were recorded in a mid-stage clinical trial of a treatment for a genetic disorder that affects the nervous system.

Write to Rob Curran at

(END) Dow Jones Newswires

04-15-24 1744ET